Actively Recruiting
Phase 2 Study of Nivolumab Alone or with Relatlimab or Ipilimumab for Treating Advanced or Metastatic Basal Cell Carcinoma
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2026-04-29
57
Participants Needed
1
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of nivolumab alone or combined with relatlimab or ipilimumab in patients with locally-advanced unresectable or metastatic basal cell carcinoma. This phase 2, open-label study aims to explore how well these treatments work in different groups of patients based on their prior treatment history, including those who have never received certain therapies and those whose disease has progressed after previous treatments. Participants will be assigned to one of three groups Cohort A includes treatment-nave patients who receive nivolumab 480 mg intravenously every 4 weeks for up to 48 weeks. Cohort B involves patients with progression after nivolumab plus relatlimab who receive nivolumab 240 mg plus ipilimumab 1 mgkg every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks. Cohort C includes patients with progression after nivolumab who receive nivolumab 480 mg plus relatlimab 480 mg every 4 weeks for up to 48 weeks. Patients in Cohort A who experience disease progression may move to Cohort B or C if appropriate. During the study, participants will undergo scheduled visits, laboratory tests, and treatment administration according to their cohort. Researchers will measure outcomes such as objective response rate over 5 years, progression-free survival, duration of response, and overall survival. Safety monitoring will be continuous, and study participation will last according to the treatment schedule and follow-up assessments.
CONDITIONS
Brief Title
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Research Team
L
Lisa Kelemen, MSN, RN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here